Literature DB >> 16169463

The Akt-mTOR tango and its relevance to cancer.

Nissim Hay1.   

Abstract

The downstream effector of PI3K, Akt, is frequently hyperactivated in human cancers. A critical downstream effector of Akt, which contributes to tumorigenesis, is mTOR. In the PI3K/Akt/mTOR pathway, Akt is flanked by two tumor suppressors: PTEN, acting as a brake upstream of Akt, and TSC1/TSC2 heterodimer, acting as a brake downstream of Akt and upstream of mTOR. In the absence of the TSC1/TSC2 brake, mTOR activity is unleashed to inhibit Akt via an inhibitory feedback mechanism. Two recent studies used mouse genetics to assess the roles of PTEN and TSC2 in cancer, underscoring the importance of Akt-mTOR interplay for cancer progression and therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16169463     DOI: 10.1016/j.ccr.2005.08.008

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  279 in total

1.  PDK1 regulates vascular remodeling and promotes epithelial-mesenchymal transition in cardiac development.

Authors:  Qiuting Feng; Ruomin Di; Fang Tao; Zai Chang; Shuangshuang Lu; Wenjing Fan; Congjia Shan; Xinli Li; Zhongzhou Yang
Journal:  Mol Cell Biol       Date:  2010-05-10       Impact factor: 4.272

Review 2.  Well-differentiated pancreatic neuroendocrine tumors: from genetics to therapy.

Authors:  Roeland F de Wilde; Barish H Edil; Ralph H Hruban; Anirban Maitra
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-02-07       Impact factor: 46.802

3.  Aloe-emodin suppresses prostate cancer by targeting the mTOR complex 2.

Authors:  Kangdong Liu; Chanmi Park; Shengqing Li; Ki Won Lee; Haidan Liu; Long He; Nak Kyun Soung; Jong Seog Ahn; Ann M Bode; Ziming Dong; Bo Yeon Kim; Zigang Dong
Journal:  Carcinogenesis       Date:  2012-04-24       Impact factor: 4.944

Review 4.  ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor identified using the JFCR39 drug discovery system.

Authors:  De-xin Kong; Takao Yamori
Journal:  Acta Pharmacol Sin       Date:  2010-08-23       Impact factor: 6.150

5.  Reduction of Pten dose leads to neoplastic development in multiple organs of Pten (shRNA) mice.

Authors:  Hong Shen-Li; Susan Koujak; Matthias Szablocs; Ramon Parsons
Journal:  Cancer Biol Ther       Date:  2010-12-01       Impact factor: 4.742

6.  Dietary energy balance modulates prostate cancer progression in Hi-Myc mice.

Authors:  Jorge Blando; Tricia Moore; Stephen Hursting; Guiyu Jiang; Achinto Saha; Linda Beltran; Jianjun Shen; John Repass; Sara Strom; John DiGiovanni
Journal:  Cancer Prev Res (Phila)       Date:  2011-09-27

Review 7.  A new link between epigenetic progenitor lesions in cancer and the dynamics of signal transduction.

Authors:  Winston Timp; Andre Levchenko; Andrew P Feinberg
Journal:  Cell Cycle       Date:  2009-02-03       Impact factor: 4.534

8.  Everolimus inhibits anti-HLA I antibody-mediated endothelial cell signaling, migration and proliferation more potently than sirolimus.

Authors:  Y-P Jin; N M Valenzuela; M E Ziegler; E Rozengurt; E F Reed
Journal:  Am J Transplant       Date:  2014-03-01       Impact factor: 8.086

9.  The impact of metformin use on recurrence and cancer-specific survival in clinically localized high-risk renal cell carcinoma.

Authors:  A Ari Hakimi; Ling Chen; Philip H Kim; Daniel Sjoberg; Leonard Glickman; Marc R Walker; Paul Russo
Journal:  Can Urol Assoc J       Date:  2013 Nov-Dec       Impact factor: 1.862

10.  Negative Regulation of AKT Activation by BRCA1.

Authors:  Tao Xiang; Amiko Ohashi; Yuping Huang; Tej K Pandita; Thomas Ludwig; Simon N Powell; Qin Yang
Journal:  Cancer Res       Date:  2008-12-15       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.